The detection of mutated antigens involves sequencing the tumor DNA and comparing it to normal tissue DNA from the same patient. Advanced technologies like [next-generation sequencing]() (NGS) and bioinformatics tools are used to identify and validate these unique mutations. Once identified, the mutated sequences are analyzed to predict their potential to be recognized by the immune system.
